PROGNOSTIC FACTORS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)INFECTED PATIENTS ON CHRONIC HAEMODIALYSIS

Ivo Laranjinha, Patrícia Matias, Jorge Dickson, Hermínia Estibeiro, Helena Boquinhas, José Diogo Barata

Hospital de Santa Cruz, Nephrology department, Carnaxide, Portugal

INTRODUCTION

- Kidney disease is an important complication of human immunodeficiency virus (HIV) infection¹.
- Since the introduction of highly active antiretroviral therapy (HAART), mortality in HIVpositive patients has decreased markedly. Simultaneously, the number of HIV-infected patients on dialysis has increased².
- Nevertheless, the prognostic factors of these patients in chronic haemodialysis (HD) are still poorly clarified.

AIM

The aim of this study was to identify the factors that can influence the survival of HIV-infected patients in chronic HD.

METHODS / POPULATION

- Single-center retrospective cohort study of HIV-infected patients on maintenance HD (> 3 months) from January 2009 through November 2014.
- All patients were dialyzed with low-flux membranes.
- Clinical, demographic and laboratory data were obtained from electronic clinical process consultation.
- Statistical analysis: Student, $\chi 2$ or Wilcoxon test to compare groups and logistic regression for multivariable analysis. A p < 0.05 was considered significant.

	Age (years)	53.5 ± 11.5
	Gender (male)	31 (70.5%)
	Race (Caucasian)	25 (56.8%)
	Deads [n (%)]	17 (38.6%)
Zs	Survival (months)	30.8
	Time on HD (months)	40.6
	Duration of HIV-infection at HD beginning (months)	132.2
	HIV: Type 1/ Type 2 / Types 1 and 2	34 (77.3%) / 8 (18.2%) / 2 (4.5%)
POPULATION 44 PATIENTS	AIDS at HD beginning	29 (76.3%)
0 44	Under HAART at HD start	30 (76.9%)
	Co-infected with VHC / VHB	13 (29.5%) / 6 (13.6%)
	Diabetes	7 (15.9%)
	Vascular access: Fistula / Graft / Catheter	16 (36.4%) / 7 (15.9%) / 20 (45.5%)
	HIV transmission: sexual / iv drugs	30 (68.2%) / 11 (25%)


^{*} Values expressed as mean±SD, median or frequencies [n (%)]

RESULTS


VARIABLES	Patients alive (n=27)	Patients who died (n=17)	p
Age (years)	55.0 ± 10.9	51.3 ± 12.5	NS
Gender (male)	16 (59.3%)	15 (88.2%)	NS
Race (black)	12 (44.4%)	13 (81.3%)	0.026
Diabetes (%)	5 (18.5%)	2 (4.5%)	NS
Vascular access (%) Fistula / Graft / Catheter	40.7 / 14.8 / 44.4	31.3 / 18.8 / 50	NS
Albumin (g/dL)	3.3 ± 0.5	2.7 ± 0.7	0.010
Co-infected			
HCV	5 (18.5)	1 (5.9)	NS
HBV	6 (22.2)	7 (41.2)	NS
Duration of HIV infection (months)	150	38	0.028
Type of HIV (%) Type 1 / Type 2 / Type 1 and 2	77.8 / 18.5 / 3.7	76.5 / 17.6 / 5.9	NS
Transmission (%) Homosexual /Heterosexual /iv drug user	7.4 / 74.1 / 14.8	5.9 / 41.2 / 41.2	NS
AIDS at HD beginning	16 (72.7%)	13 (81.3%)	NS
Number of opportunistic infections	0	1	0.013
Number of hospitalizations	2	3	NS
Log of viral load at HD beginning	3.3 ± 1.3	4.8 ± 1.6	0.044
CD4+ number at HD beginning	244.9 ± 187	287.6 ± 198	NS
* Values expressed as mean±SD, median or frequencies [n (%)]			


During the study, 17 of the 44 (39%) patients died.

Those who died had a shorter duration of HIV infection, a higher viral load and a lower serum albumin at the beginning of HD. They also presented more opportunistic infections during maintenance on HD.



By Kaplan-Meier analysis, we found that patients co-infected with hepatitis C, with serum albumin less than 3 g/dL at the beginning of HD and with HIV transmission by injection drug use had a lower survival.





CONCLUSIONS / DISCUSSION

Our study shows that in this cohort of HIV-infected patients on chronic HD:

- Unlike other studies³, the mortality of these patients was related to shorter duration of known HIV-infection and black race.
- As already described ^{4,5,7}, higher viral load and more opportunistic infections were associated with higher mortality. However, other authors ^{6,7} have found this association also with lower CD4+ counts.
- In accordance with the literature, hepatitis C co-infection⁴, lower serum albumin⁴ and HIV transmission by injection drug use⁵ was associated with a lower survival.
- The survival in our cohort (1-yr survival of 82.5%) was similar to which has been reported in the literature^{3,4}.

REFERENCES

- ¹ M Bickel, W Marben *et.al*. End-stage Renal Disease and Dialysis in HIV-positive Patients. HIV Medicine. 2013;14(3):127-135
- ² Ahuja TS, Borucki M, Grady J: Highly active antiretroviral therapy improves survival of HIV-
- infected hemodialysis patients. Am J Kidney Dis 36: 574–580, 2000

 ³ Ahuja TS, Grady J, and KHAN S. Changing Trends in the Survival of Dialysis Patients with
- Human Immunodeficiency Virus in the United States. J Am Soc Nephrol 13: 1889–1893, 2002
- ⁴ Tourret J, Tostivint I, et. al. Outcome and Prognosis Factors in HIV-Infected Hemodialysis Patients. Clin J Am Soc Nephrol 1: 1241–1247, 2006
- ⁵ Rodriguez R, Mendelson M, et.al. Determinants of Survival among HIV-Infected Chronic Dialysis Patients. J Am Soc Nephrol 14: 1307–1313, 2
- ⁶ Barbiano di Belgiojoso G, et.al. HIV infection in dialysis centers in Italy: A nationwide multicenter study. J Nephrol 11: 249–254, 1998⁵
- ⁷ Perinbasekar S1, Brod-Miller C, Pal S, Mattana J. Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol. 1996;16(4):280-6.

Contact of first author: ivolaranjinha@gmail.com





